Multiple chemical classes of ghrelin receptor ligands (peptides, peptidomimetics, small molecules) were in development by 2007, with diverse clinical applications from GH deficiency to cachexia to gastroparesis.
Key findingBy 2007, ghrelin receptor drug development included peptide agonists, peptidomimetics (MK-677, capromorelin), non-peptide agonists, inverse agonists,
What the researchers found
By 2007, ghrelin receptor drug development included peptide agonists, peptidomimetics (MK-677, capromorelin), non-peptide agonists, inverse agonists, and biased ligands targeting GH deficiency, cachexia, gastroparesis, and obesity — the most diverse GPCR drug pipeline.
Why it matters
Relevant for ghrp, peptide-design, receptor-signaling.
How the study worked
review study on ghrp, peptide-design.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Recent developments in ghrelin receptor ligands.
ChemMedChem, 2(9), 1242-59
Citation
Moulin, Aline; Ryan, Joanne; Martinez, Jean; Fehrentz, Jean-Alain. (2007). Recent developments in ghrelin receptor ligands.. ChemMedChem, 2(9), 1242-59.